2021, the year that redrew the CBD framework in France

2021 began in the wake of the Kanavape judgment handed down by the Court of Justice of the European Union on 19 November 2020. That decision recognised that a member state may not prohibit the marketing of CBD lawfully produced in another country of the Union, provided it is extracted from the whole hemp plant. It opened the way to a more favourable reading of the CBD trade in France, after years of uncertainty over the status of the molecule.

At the end of 2021, a ministerial order attempted to ban the sale and possession of raw hemp flowers and leaves intended for consumption, while authorising processed extracts. The text provoked a strong reaction from specialist shops, for which flowers represent a significant share of the business. The Conseil d'État, hearing an urgent application, suspended the order as early as 24 January 2022, finding serious doubt as to its lawfulness.

This swift suspension illustrates a recurring tension in the sector: regulatory texts change faster than professionals can adapt to them, and sometimes faster than their own legal soundness.

For sellers, this episode had three concrete consequences.

• A gradual clarification of the fact that selling raw flowers and leaves remains possible as long as the THC content of the finished product complies with the regulatory threshold.
• A reinforced need for traceability: analysis certificates, batch origin, compliance displayed in the shop.
• Greater caution in communication, with retailers avoiding any claim that could be read as encouraging a diverted use.

The Conseil d'État confirmed this position on the merits a year later, definitively annulling the ban on flowers and leaves on 29 December 2022.

In parallel, 2021 also marked the start of another European project: the classification of cannabinoids intended to be ingested in the "novel food" category by the EFSA. This status implies that a CBD product to be swallowed (oil, capsule, gummy) must, in time, be the subject of a marketing authorisation based on a food safety dossier. That project, still under examination years later, shapes the way manufacturers document their extracts today.

Several markers laid down in 2021 continue to apply. The THC threshold in the finished product remains the central benchmark for judging whether a product is lawful. The distinction between raw flowers and processed extracts has lost some of its legal relevance since the 2022 annulment, but it remains useful for understanding the history of the sector. Finally, novel food status continues to weigh on ingested products, without having fully stabilised the market.

For a broader overview of the texts that govern the sale of flowers today, our article on the order that sought to ban CBD flowers goes back over this sequence in detail.

Is the order from the end of 2021 still in force?

No. It was suspended by the Conseil d'État as early as January 2022, then definitively annulled on the merits in December 2022. Selling raw hemp flowers and leaves remains possible, subject to compliance with the THC threshold.

What does the Kanavape case law change for a buyer in France?

It confirmed that CBD lawfully extracted from the whole plant in another member state of the European Union cannot be banned in France on the sole ground of its origin.

Does novel food status concern all CBD products?

It concerns products intended to be ingested, such as oils, capsules or gummies. Topical cosmetics fall under a separate European regulation specific to cosmetic products.

Why does the CBD sector change framework so often?

Because CBD sits at the crossroads of several sets of rules — agricultural, food and public health — whose texts were not always designed together. Each clarification from the courts fills in these grey areas.